155 related articles for article (PubMed ID: 31277053)
41. Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
Chen WR; Chen YD; Tian F; Yang N; Cheng LQ; Hu SY; Wang J; Yang JJ; Wang SF; Gu XF
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27940956
[TBL] [Abstract][Full Text] [Related]
42. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.
Gordin J; Haider A; Swaminathan RV; Kim LK; Minutello RM; Bergman G; Wong SC; Feldman DN
Am J Cardiol; 2012 Nov; 110(10):1397-404. PubMed ID: 22858186
[TBL] [Abstract][Full Text] [Related]
43. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
Pelliccia F; Pasceri V; Marazzi G; Rosano G; Greco C; Gaudio C
Am Heart J; 2012 Jun; 163(6):1019-23. PubMed ID: 22709755
[TBL] [Abstract][Full Text] [Related]
44. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
[TBL] [Abstract][Full Text] [Related]
45. The periprocedural myocardial damage prevention during elective percutaneous coronary intervention as a result of pharmacological preconditioning with an oral form of nicorandil in patients with stable coronary artery disease. Pilot study.
Gostishchev RV; Soboleva GN; Samko AN; Rogoza AN; Minasyan AA
Ter Arkh; 2018 Sep; 90(9):53-59. PubMed ID: 30701736
[TBL] [Abstract][Full Text] [Related]
46. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
Read PA; Hoole SP; White PA; Khan FZ; O'Sullivan M; West NE; Dutka DP
Circ Cardiovasc Interv; 2011 Jun; 4(3):266-72. PubMed ID: 21586690
[TBL] [Abstract][Full Text] [Related]
47. Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.
Huang M; Wei R; Wang Y; Su T; Li Q; Yang X; Chen X
Ann Med; 2017 Nov; 49(7):552-561. PubMed ID: 28286967
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.
Mayer K; Hein-Rothweiler R; Schüpke S; Janisch M; Bernlochner I; Ndrepepa G; Sibbing D; Gori T; Borst O; Holdenrieder S; Kupka D; Petzold T; Bradaric C; Okrojek R; Leistner DM; Trippel TD; Münzel T; Landmesser U; Pieske B; Zeiher AM; Gawaz MP; Hapfelmeier A; Laugwitz KL; Schunkert H; Kastrati A; Massberg S
JAMA Cardiol; 2021 Jul; 6(7):753-761. PubMed ID: 33787834
[TBL] [Abstract][Full Text] [Related]
49. The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention.
Aslanabadi N; Safaie N; Asgharzadeh Y; Houshmand F; Ghaffari S; Garjani A; Dousti S; Hamishehkar H; Entezari-Maleki T
Cardiovasc Ther; 2016 Aug; 34(4):254-60. PubMed ID: 27214383
[TBL] [Abstract][Full Text] [Related]
50. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
[TBL] [Abstract][Full Text] [Related]
51. A Randomized Trial of Creatine-kinase Leak After Rosuvastatin in Elective Percutaneous Coronary Intervention (CLEAR-PCI).
Martins KB; Mattos LA; Sousa AG; Sousa JE; Abzaid A; Feres F; de Ribamar JC; Staico R; Costa RA; Chaves AJ
J Interv Cardiol; 2015 Aug; 28(4):339-47. PubMed ID: 26086603
[TBL] [Abstract][Full Text] [Related]
52. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
[TBL] [Abstract][Full Text] [Related]
53. Association of major adverse cardiovascular events and cardiac troponin-I levels following percutaneous coronary intervention: a three-year follow-up study at a single center.
Huang ZS; Zheng ZD; Zhang JW; Tang LL; Zhou LL; Li SH; Xie XJ; Dong RM; Zhu JM; Liu JL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3981-3992. PubMed ID: 32329875
[TBL] [Abstract][Full Text] [Related]
54. Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes.
Zeng RX; Li XL; Zhang MZ; Guo YL; Zhu CG; Guo LH; Li S; Zhang Y; Li JJ
Atherosclerosis; 2014 Dec; 237(2):536-43. PubMed ID: 25463086
[TBL] [Abstract][Full Text] [Related]
55. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
56. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
[TBL] [Abstract][Full Text] [Related]
57. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
58. Impact of crossing technique on the incidence of periprocedural myocardial infarction during chronic total occlusion percutaneous coronary intervention.
Stetler J; Karatasakis A; Christakopoulos GE; Tarar MN; Amsavelu S; Patel K; Rangan BV; Roesle M; Resendes E; Grodin J; Abdullah S; Banerjee S; Brilakis ES
Catheter Cardiovasc Interv; 2016 Jul; 88(1):1-6. PubMed ID: 27014962
[TBL] [Abstract][Full Text] [Related]
59. Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center.
Nozari Y; Eshraghi A; Talasaz AH; Bahremand M; Salamzadeh J; Salarifar M; Pourhosseini H; Jalali A; Mortazavi SH
Am J Cardiovasc Drugs; 2018 Jun; 18(3):213-221. PubMed ID: 29322434
[TBL] [Abstract][Full Text] [Related]
60. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
Briguori C; Visconti G; Focaccio A; Golia B; Chieffo A; Castelli A; Mussardo M; Montorfano M; Ricciardelli B; Colombo A
J Am Coll Cardiol; 2009 Dec; 54(23):2157-63. PubMed ID: 19664895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
